Zoeken Afbeeldingen Maps Play YouTube Nieuws Gmail Drive Meer »
Inloggen
Gebruikers van een schermlezer: klik op deze link voor de toegankelijkheidsmodus. De toegankelijkheidsmodus beschikt over dezelfde essentiële functies, maar werkt beter met uw lezer.

Patenten

  1. Geavanceerd zoeken naar patenten
PublicatienummerWO1990013641 A1
PublicatietypeAanvraag
AanvraagnummerPCT/US1990/002656
Publicatiedatum11 nov 1990
Aanvraagdatum10 mei 1990
Prioriteitsdatum10 mei 1989
Ook gepubliceerd alsCA2055435A1, EP0471796A1, EP0471796A4
PublicatienummerPCT/1990/2656, PCT/US/1990/002656, PCT/US/1990/02656, PCT/US/90/002656, PCT/US/90/02656, PCT/US1990/002656, PCT/US1990/02656, PCT/US1990002656, PCT/US199002656, PCT/US90/002656, PCT/US90/02656, PCT/US90002656, PCT/US9002656, WO 1990/013641 A1, WO 1990013641 A1, WO 1990013641A1, WO 9013641 A1, WO 9013641A1, WO-A1-1990013641, WO-A1-9013641, WO1990/013641A1, WO1990013641 A1, WO1990013641A1, WO9013641 A1, WO9013641A1
UitvindersEli Gilboa, Bruce Sullenger
AanvragerSloan Kettering Inst Cancer
Citatie exporterenBiBTeX, EndNote, RefMan
Externe links:  Patentscope, Espacenet
Cellules eucaryotes transformees de maniere stable comprenant un adn etranger susceptible d'etre transcrit sous la direction d'un promoteur pol iii
WO 1990013641 A1
Samenvatting
Une cellule eucaryote transformée de manière stable comprend un promoteur pol III et un ADN étranger susceptible d'être transcrit sous la direction du promoteur pol III. Un vecteur rétroviral comprend un ARN-t chimérique introduit dans la séquence répétitive teerminale longue en 3' du vecteur rétroviral.
Beschrijving  beschikbaar in het Engels
Patentcitaties
Geciteerd patent Aanvraagdatum Publicatiedatum Aanvrager Titel
US4497796 *8 dec 19825 feb 1985The Regents Of The University Of CaliforniaGene transfer in intact mammals
Niet-patentcitaties
Referentie
1 *Cell, Volume 43, published December 1985. J. TOBIAN, et al. "tRNA nuclear transport: defining the critical regions of human tRNA (i)(met) by point mutagenesis" pp. 415-422. see entire article.
2 *CHEMICAL ABSTRACTS, Volume 111, No. 13, issued 1989, September 25 (Columbus, Ohio, U.S.A.), E. GILBOA, et al. "Retroviral gene transfer: applications to human therapy" see page 110247, column 1, the Abstract No. 110249f, Adv. Exp. Biol. Med. 1988, 241 (Mol. Biol. Hemopoesis), 29-33 (Eng).
3 *Cold Spring Harbor Sym. on Mol. Biol., Volume LI. published 1986. A. MILLER, et al. "Transfer of genes into human somatic cells using retrovirus vectors" pp. 1013-1019. see entire article.
4 *EMBO J., Volume 6, Number 10, published October 1987. P. JENNINGS, et al. "Inhibition of SV40 replicon function by engineered antisense RNA transcribed by RNA polymerase III" pp. 3043-3047. see entire article.
5 *EMBO J., Volume 6, Number 2, published February 1987. N. TAKAMATSU, et al. "Expression of bacterial chloramphenicol acetyltransferase gene in tobacco plants mediated by TMV-RNA" pp. 307-311. see entire article.
6 *J. Virol., Volume 63, Number 2, published February 1989. T. VON RUDEN, et al. "Inhibition of human T-cell leukemia virus type I replication in primary human T cells that express antisense RNA" pp. 677-682. see entire article.
7 *J. Virol., Volume 63, Number 3, published March 1989. M. HADZOPOULOU-CLADARAS, et al. "The rev (trs/art) protein of human immunodeficiency virus type 1 affects viral mRNA and protein expression via a cis-acting sequence in the env region" pp. 1265-1274 see entire article.
8 *Nature, Volume 323, published 25 September 1986. J. ZARLING, et al. "T-cell responses to human AIDS virus in macaques immunized with recombinant virus" pp. 344-346. see entire article.
9 *Nature, Volume 335, published 29 September 1988. A. FRIEDMAN, et al. "Expression of a truncated viral trans-activator selectively impedes lytic infection by its cognate virus" pp. 452-454. see entire article.
10 *Nature, Volume 335, published 29 September 1988. D. BALTIMORE "Intracellular Immunization" pp. 395-396. see entire article.
11 *Nucl. Acid. Res., Volume 11, Number 6, published 1983. D.JOLLY, et al. "Elements in the long terminal repeat of murine retroviruses stable transformation by thymidine kinase gene", pp. 1855-1872. see entire document.
12 *Nucl. Acid. Res., Volume 12, Number 2, published 1984. S. ADENIYI-JONES, et al. "Generation of long read-through transcripts in vivo and in vitro by deletion of 3' termination and processing sequences in the human tRNA (i)(met) gene" pp. 1101-1115. see entire article.
13 *See also references of EP0471796A1
Verwijzingen naar dit patent
Citerend patent Aanvraagdatum Publicatiedatum Aanvrager Titel
WO1994026877A1 *17 mei 199424 nov 1994Univ CaliforniaTherapie genique ribozymique contre l'infection par le vih et contre le sida
WO1995021912A1 *14 feb 199517 aug 1995Australian Red CrossSouches non pathogenes de vih-1
WO1995027783A1 *5 april 199519 okt 1995Joshi Sukhwal SadnaInhibition de la multiplication du vih-1 dans des cellules de mammiferes
WO2001029070A218 okt 200026 april 2001Genentech IncRecepteur tccr de cytokine de type i
WO2007038658A226 sept 20065 april 2007Medarex IncConjugues anticorps-medicament et leurs methodes d'utilisation
WO2009102488A213 feb 200920 aug 2009Univ TuftsModèle humanisé de la formation du complexe d’attaque membranaire (mac) sur la rétine murine et compositions, trousses et procédés de traitement de la dégénérescence maculaire
DE4225094A1 *29 juli 19924 nov 1993Frank Andreas Harald MeyerMedikament zur gentherapeutischen behandlung von menschen, tieren und pflanzen, insbesondere zur blockierung der virenvermehrung und der tumorgene sowie verfahren zur herstellung des medikaments
EP0596901A1 *27 mei 199218 mei 1994City Of HopeMOLECULES CHIMERIQUES DE RIBOZYMES D'ARNt?LYS
EP0971033A221 jan 199212 jan 2000IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY & MEDICINEEssai et modèle pour la maladie d'Alzheimer
EP1666591A125 juni 19967 juni 2006Immunex CorporationCytokine induisant l'apoptose
EP1757618A222 maart 200128 feb 2007Curagen CorporationProteines associées a l'angiogenese et acides nucleiques codant pour les dites proteines
EP1772515A112 mei 200011 april 2007Immunex CorporationImmunorégulateur de la famille nommée 'récepteurs semblables à des récepteurs de leucocytes de type immunoglobuline' (LIR)
EP1865061A214 mei 199912 dec 2007Genentech, Inc.Polypeptides allogéniques IL-17 et utilisations thérapeutiques
EP1944317A229 aug 200116 juli 2008Genentech, Inc.Polypeptides sécrétés et transmembranaires, et acides nucléiques les codant
EP1953173A122 mei 20006 aug 2008Genentech, Inc.Polypeptides sécrétés et transmembranaires, et acides nucléiques les codant
EP1956030A122 mei 200013 aug 2008Genentech, Inc.Polypeptides sécrétés et transmembranaires, et acides nucléiques les codant
EP1995321A218 juli 200626 nov 2008Genentech, Inc.Nouvelle dislocation de gènes, compositions et procédés correspondants
EP2002714A116 nov 200617 dec 2008Genentech, Inc.Nouvelles ruptures génétiques, compositions et procédés associés à celles-ci
EP2050335A19 feb 200722 april 2009Genentech, Inc.Dislocation de gènes, compositions et procédés correspondants
EP2075334A122 juni 20011 juli 2009Genentech, Inc.Acides nucléiques EG-VEGF et polypeptides et procédés d'utilisation
EP2082645A118 april 200729 juli 2009Genentech, Inc.Nouvelle dislocation de gènes, compositions et procédés correspondants
EP2110434A124 feb 200321 okt 2009Genentech, Inc.Recepteur de cytokine de type 1 GLM-R
EP2163625A120 dec 200017 maart 2010Genentech, Inc.Polypeptides homologues IL-17 et IL-17R et utilisations thérapeutiques
EP2186402A118 mei 200619 mei 2010Genentech, Inc.Modèles d'animaux knock-out et leur utilisation
EP2228446A11 dec 200015 sept 2010Genentech, Inc.Polypeptides secrétés et transmembranaires et acides nucléiques codant pour ceux-ci
EP2258848A120 dec 20008 dec 2010Genentech, Inc.Polypeptides allogéniques IL-17 et utilisations thérapeutiques
EP2266986A131 mei 200229 dec 2010Medarex, Inc.Cytotoxines, promedicaments, lieurs et stabilisateurs utiles pour ceux-ci
EP2277908A22 juni 200426 jan 2011Genentech, Inc.Polypeptides hétérologues IL-14A/F, anticorps et utilisations thérapeutiques associées
EP2290081A220 dec 20002 maart 2011Genentech, Inc.Polypeptides allogéniques IL-17 et utilisations thérapeutiques
EP2333069A214 mei 199915 juni 2011Genentech, Inc.Utilisations thérapeutiques de polypeptides homologues de IL-17
EP2354163A226 sept 200610 aug 2011Medarex, Inc.Conjugué d'un anticorps anti-cd4 ou anti-psma et duocarmycine
EP2450050A120 nov 20079 mei 2012Genentech, Inc.Polypeptides hétérologues IL-14A/F et utilisations thérapeutiques associées
US5583035 *14 nov 199410 dec 1996Bayer AktiengesellschaftHIV antisense expression vectors
US5631360 *5 mei 199520 mei 1997Ribozyme Pharmaceuticals, Inc.N-phthaloyl-protected 2'-amino-nucleoside phosphoramdites
US5670361 *17 mei 199423 sept 1997The Regents Of The University Of CaliforniaInsertion retrovirus into nucleic acid
US5686599 *2 mei 199511 nov 1997Ribozyme Pharmaceuticals, Inc.Synthesis, deprotection, analysis and purification of RNA and ribozymes
US5804683 *5 mei 19958 sept 1998Ribozyme Pharmaceuticals, Inc.Reacting with an alkylamine or ammonium hydroxide/alkylamine mixture at 60-70 degrees c. for 5 to 15 minutes in order to remove any exocyclic protecting groups
US5831071 *29 aug 19973 nov 1998Ribozyme Pharmaceuticals, Inc.Synthesis deprotection analysis and purification of RNA and ribozymes
US5854038 *14 okt 199429 dec 1998University Research CorporationLocalization of a therapeutic agent in a cell in vitro
US5871958 *3 nov 199416 feb 1999Duke UniversityViricides; genetic engineering
US5902880 *10 nov 199411 mei 1999Ribozyme Pharmaceuticals, Inc.Non-naturally occuring rna having ribonucleotides at 3' and 5' terminals which hydrogen bond; increases stability; increases level of production of exogenous rna; for gene therapy
US5955644 *8 aug 199621 sept 1999M.D. Anderson Cancer CenterMutants, mice
US6015661 *7 juni 199518 jan 2000The Macfarlane Burnet Centre For Medical Research LimitedMethods for the detection of non-pathogenic HIV-1 strains containing deletions in the Nef coding region and U3 region of the LTR
US6057489 *12 sept 19962 mei 2000M.D. Anderson Cancer CenterMouse cell heterozygous for mutation in recombinational repair pathway; used in screening for proteins that rescue the senescence phenotype in mmrad51/p53-deficient cells
US6132962 *16 juni 199717 okt 2000The Regents Of The University Of CaliforniaRetroviral vectors comprising an anti-hiv or other nucleic acid
US6146886 *7 aug 199514 nov 2000Ribozyme Pharmaceuticals, Inc.Transcribed non-naturally occurring rna having a stabilizing intramolecular stem formed by base-pairing interactions between 3' region and 5' complementary nucleotides; antisense agents; decoys; ribozymes; agonist/antagonist rna
US6162898 *21 aug 199819 dec 2000Duke UniversityProtein having one or more mutations from amino acid position 68 to 90 and which suppresses the phenotypic expression of the wild-type rev gene of human immunodeficiency virus-1; viricides
US62516752 juni 199526 juni 2001Duke UniversityMethods utilizing mutant rev genes encoding transdominant repressors of HIV replication
US628780930 dec 199811 sept 2001Novartis AgProtein which represses phenotypic expression of wild-type rex gene of human t-cell leukemia/lymphoma virus-1 or -2 and/or wild-type rev gene of human immunodeficiency virus-1; viricides; prophylaxis
US633915021 aug 199815 jan 2002Duke UniversityA genetically mutated viricide gene; therapy for lymphadenopathy associated virus
US635309817 juni 19985 maart 2002Ribozyme Pharmaceuticals, Inc.Deprotecting and purifying rna
US643711727 juli 199920 aug 2002Ribozyme Pharmaceuticals, Inc.Anion exchange high-performance liquid chromatography; elution, recovering
US64691582 mei 199522 okt 2002Ribozyme Pharmaceuticals, IncorporatedLoading a mixture of rna on to an anion exchange high-performance liquid chromatography (hplc) column, eluting with buffer and collecting eluate; purifying in enzymatically active form
US664975128 mei 200218 nov 2003Sirna Therapeutics, Inc.Synthesis, deprotection, analysis and purification of RNA and ribozymes
US667017719 juni 199830 dec 2003Advanced Research And Technology Institute, Inc.Infecting cells with a retrovirus in the presence of an immobilized material including a ligand which bings to the cell and a ligand which binds to the retrovirus
US67769866 juni 199717 aug 2004Novartis AgInhibition of HIV-1 replication by antisense RNA expression
US68525352 aug 20008 feb 2005Sirna Therapeutics, Inc.Polymerase III-based expression of therapeutic RNAS
US704181730 aug 20029 mei 2006Sirna Therapeutics, Inc.Synthesis, deprotection, analysis and purification of RNA and ribozymes
US708397913 sept 19991 aug 2006Indiana University FoundationMethods for enhanced retroviral-mediated gene transfer
US717311511 jan 20016 feb 2007Genentech, Inc.Stra6 polypeptides
US723563313 nov 200226 juni 2007Genentech, Inc.Comprises membrane protein for use in the diagnosis, prevention and treatment of tumor disorders
US765937525 juni 20079 feb 2010Immunex CorporationHuman IL-1 epsilon DNA and polypeptides
US77051954 juni 200327 april 2010Genentech, Inc.Screening method
US774143922 mei 200622 juni 2010Genentech, Inc.For stimulating release of tumor necrosis factor and/or cellular prolifefration/differentiation of chondrocytes by contacting blood w/polypeptide; diagnosis cancer
US775946715 juni 200620 juli 2010Indiana University Research And Technology CorporationEnhanced mediated DNA transfer
US785527831 okt 200721 dec 2010Genentech, Inc.Antibodies to Stra6 polypeptides
US793965018 juli 200610 mei 2011Genentech, Inc.Stra6 polypeptides
US832418213 feb 20094 dec 2012Tufts UniversityHumanized model of membrane attack complex (MAC) formation on murine retina and compositions, kits and methods for treatment of macular degeneration
US853591215 okt 201017 sept 2013Genentech, Inc.Chimeric fibroblast growth factors with altered receptor specificity
Classificaties
Internationale classificatieA61K39/21, A01K67/027, A61P37/04, C12N15/82, A01H5/00, C12N15/09, C12N15/79, C12N15/85, C12N5/10, C12P21/00, C12N15/67, A61K38/00, A61P31/12, A61K31/70, C12R1/91, C12N15/11, C12N15/113
Coöperatieve classificatieC12N15/85, A01K67/027, C12N15/67, C12N15/1132, C12N15/8218, C12N15/79, C12N15/11, C12N2310/13
Europese classificatieC12N15/67, C12N15/85, C12N15/79, C12N15/82B4, C12N15/11, A01K67/027, C12N15/113A1
Juridische gebeurtenissen
DatumCodeGebeurtenisBeschrijving
30 juli 1998WWW
Ref document number: 1990909233
Country of ref document: EP
26 feb 1992WWP
Ref document number: 1990909233
Country of ref document: EP
10 dec 1991WWE
Ref document number: 1990909233
Country of ref document: EP
7 nov 1991WWE
Ref document number: 2055435
Country of ref document: CA
7 nov 1991ENP
Ref country code: CA
Ref document number: 2055435
Kind code of ref document: A
Format of ref document f/p: F
15 nov 1990AK
Kind code of ref document: A1
Designated state(s): CA JP US
15 nov 1990AL
Kind code of ref document: A1
Designated state(s): AT BE CH DE DK ES FR GB IT LU NL SE